Inclusion Criteria:  Meet the Diagnostic Criteria for AIDS or HIV Infection (WS 293-2019); Age 18 or above (included 18); Continuous administration of a TDF-based triple ART regimen with a backbone of non-nucleoside reverse transcriptase or protease inhibitors ≥24 weeks and ongoing use; Maintaining virological suppression (viral load < 50 copies/mL) for ≥ 24 weeks, and maintaining virological suppression at present; Glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m2 (calculated according to the CKD-EPI formula); ECG is normal; White blood cell count ≥3×109/L, Neutrophil count ≥1.5×109/L, Hemoglobin ≥90 g/L, and Platelet count ≥ 75×109/L; Alanine aminotransferase and aspartate aminotransferase ≤5×ULN, direct bilirubin ≤1.5×ULN, amylase≤2×ULN； Those who volunteered for this study and were able to complete all follow-up visits and sign the informed consent form in accordance with the protocol.  Exclusion Criteria:  In the 30 days(inclusive) before the screening period, an AIDS-related opportunistic infection or tumor occurred; History of known past HIV resistance (confirmed HIV viral load > 200 copies /ml) or resistance to any nucleoside (acid) analogues; Decompensated liver cirrhosis; Female subject who has a positive urine pregnancy test; Lactating women; Women who are unable to take a reasonable method of contraception during the trial (including the Screening Period and 30 days after discontinuation of experimental drugs); Subjects had other medical conditions requiring treatment with either of the current ART regimens or other drugs which have drug-drug interaction with B/F/TAF and cannot be discontinued. Being involved in other interventional clinical studies; Those with allergic constitution or known allergy to the components of the drug; Suffering from serious mental or neurological diseases; Suspected or confirmed history of alcohol and drug abuse; Patients who were not considered by the investigator to be suitable for participating in this clinical trial (such as weak constitution, poor compliance, etc.).